Chapter 4
Tom Newberg, chairman of the board of Plaxicor, decided after a generous break for lunch to call the directors back to the board table. They still had one very important strategic matter to cover, and it needed to get adequate attention before directors started zoning out or thinking ahead to catching their flights. It was the decision to acquire Alitec, a small local company whose yet uncertain but potentially groundbreaking technology for storing blood could get Plaxicor’s newest product to market almost 2 quarters early, give them a huge step up on competitors, and potentially give them exclusive access to the technology that competitors would soon rely on as well. Tom had prepared for the discussion and asked ...
Get Blind Spots, Biases and Other Pathologies in the Boardroom now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.
